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Purpose: To evaluate the effect of the recombinant adeno-associated virus (rAAV) vector that expresses human pigment
epithelium-derived factor (hPEDF) on reducing blood–retinal barrier (BRB) breakdown in the experimental diabetic rat
model.
Methods: Diabetes was induced by an intraperitoneal (i.p.) injection of streptozotocin (STZ) into 10-week-old male Wister
rats. rAAV2-cytomegalovirus (CMV)-hPEDF was delivered into the right eyes by intravitreal injection on the first day
after diabetes induction. The contralateral eyes received intravitreal injection of rAAV2-CMV-green fluorescent protein
as  the  paired  control.  Gene  delivery  and  expression  of  vascular  endothelial  growth  factor  (VEGF),  occludin,  and
intercellular adhesion molecule-1 (ICAM-1) were determined with reverse transciptase PCR or western blotting. BRB
breakdown changes were quantified by measuring albumin leakage from retinal blood vessels after an intravenous (i.v.)
injection of Evans blue albumin.
Results: Retinal transfection with the hPEDF gene construct led to sustained hPEDF gene expression for 6 months,
significantly suppressing VEGF mRNA expression in the retina after 1, 3, and 6 months of diabetes induced by STZ
compared with paired controls. Moreover, hPEDF dramatically reduced the levels of retinal ICAM-1 but increased the
expression of occludin. Furthermore, BRB breakdown was much lower in hPEDF-injected diabetic animals in comparison
with controls after 6 months.
Conclusions: A single intravitreal injection of rAAV2-CMV-hPEDF can relieve BRB breakdown in STZ-induced diabetic
rats for 6 months. The effect is associated with downregulation of retinal VEGF mRNA and ICAM-1 expression and a
reduction in the loss of retinal occludin induced by diabetes. The approach of gene transfer may reduce diabetic macular
edema, providing long-term protection for diabetic patients at risk of macular edema.
Diabetic macular edema (DME) can lead to considerable
vision  loss  in  diabetic  patients,  especially  in  those  with
nonproliferative diabetic retinopathy (NPDR). An increase in
vasopermeability, caused by the breakdown of the blood–
retinal barrier (BRB), is a key factor of DME [1,2]. Although
laser therapy has shown some effect on preventing partial
visual  loss,  the  current  treatments  for  DME  are  far  from
satisfactory.
Vascular endothelial growth factor (VEGF), a hypoxia-
induced angiogenic factor, is a potent vascular permeability
factor  that  can  cause  hyperpermeability  by  inducing
phosphorylation of tight junction proteins, such as occludin
and zonula occludin-1 (ZO-1) [3,4]. Studies have shown that
a high level of VEGF, found in the retina and vitreous of DME
patients, coincided with BRB breakdown [5,6]; this suggests
that VEGF may play an important role in DME formation.
Recent studies have reported that pigment epithelium-derived
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factor (PEDF), a potent angiogenic inhibitor, was found in
decreased  amounts  in  the  vitreous  of  diabetic  retinopathy
(DR) patients [7–10]. Vitreal injections of PEDF can suppress
BRB breakdown and vascular permeability induced by VEGF
[11], which implies that PEDF can take part in regulating
vascular permeability. Based on the above, we hypothesize
that an increase of retinal PEDF would antagonize VEGF and
inhibit BRB breakdown in patients with diabetes.
Intravitreal injection is the best way to deliver PEDF.
However, due to the short half-life of PEDF [12], multiple
injections  are  required  for  treatment.  However,  repeated
intraocular injections may cause increased risk of side effects,
such as vitreous hemorrhage and retinal detachment, and may
not be feasible depending upon the frequency of the injections
required. Therefore, any approach that incorporates sustained
drug delivery will improve efficacy and safety. Gene transfer
offers an alternative means for this purpose. Recombinant
adeno-associated virus vectors (AAV) have become potent
gene delivery tools in a variety of animal models that mimic
human retinal diseases because of a lack of pathogenicity,
minimal immunogenicity, stable and efficient transfection,
and the maintenance of high levels of transgene expression.
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neovascularization has been demonstrated after intraocular
injection of AAV-mediated PEDF [13]. Herein, we used AAV
vectors containing genes coding human PEDF to treat diabetic
rats and to test the long-term effects of intravitreal injection
of hPEDF on retinal permeability.
METHODS
Animals:  Ten-week-old  male  Wister  rats,  weighing
approximately 180–200 g,  were  purchased  from the China
Medical  University  Animal  Resource  Laboratory
(Shenyang,China). Care, use, and treatment of all animals
approved by the laboratory animal center and in this study
were in strict agreement with the guidelines on the care and
use of laboratory animals set forth by the laboratory animal
center of China Medical University.
Rats model of streptozotocin-induced diabetes: Diabetes was
induced  by  an  intraperitoneal  injection  of  streptozotocin
(STZ; 60 mg kg−1 in 10 mmol l−1 of citrate buffer, pH 4.4;
Sigma, Shanghai, China) into Wister rats that had been fasted
for 12 h. Blood from tail vein was used for blood glucose level
test  48  h  after  injection  and  blood  glucose  levels  were
monitored  on  a  monthly  basis.  Only  animals  with  blood
glucose  concentrations  higher  than  16.7  mmol/l  were
considered diabetic. The diabetic rats without complications
from  intravitreal  injection  (such  as  retinal  detachment,
hemorrhages,  infection)  were  divided  into  three  groups:1
month (DM1), 3 months (DM3), and 6 months (DM6). Due
to unexpected deaths, the final sample size of each group was
21 (4/25), 21 (4/25), and 20 (5/25), respectively.
Intravitreal injection of vector: Wister rats were intravitreally
injected on the first day of diabetes (the animals had a blood
glucose level higher than 16.7 mM). To avoid unnecessary
effects  on  the  retina  induced  by  some  nonexperimental
factors,  such  as  vectors  themselves  and  the  injection
procedure, both eyes of rats were injected with vector. The
rats were anesthetized with ketamine (Shandong fangming
pharmaceutical Co, Ltd, Dongming, China; 80 mg kg−1) by
intraperitoneal  injection,  and  the  pupils  dilated  with
tropicamide; then a 30-gauge needle on a Hamilton syringe
was inserted into the vitreous cavity through the sclera just
behind the limbus of the right eye, under microscopic control.
Two microliters of rAAV2-cytomegalovirus (CMV)-hPEDF
(1×1011  vector  genomes  ml−1;  AGTC  Gene  Technology
Company Ltd, Beijing, China) was injected into the vitreous
of the right eye. The contralateral eye was injected with 2 μl
of  rAAV2-CMV-green  fluorescent  protein  (GFP;  1×1011
vector genomes ml−1; AGTC Gene Technology Company Ltd)
as the paired control. In the normal control group (CON), the
right eyes were sham injected without infusing any drug as
“treatment” and the left eyes were left intact.
Histological evaluation of GFP expression: The eyes with
rAAV2-CMV-GFP injection were enucleated at 1, 3, and 6
months and then fixed in 4% paraformaldehyde for 1 h at 4 °C.
After washing thoroughly, the eyes were cut through the pars
plana and the posterior sections with retinae were embedded
in optimal cutting temperature tissue fluid (Maixin Bio,Led,
FuZhou,China)  for  sectioning.  Serials  of  10-μm  frozen
sections  were  observed  with  a  fluorescence  microscope
(Olympus, BX51, Japan).
Reverse transcriptase-PCR assessment: Normal and diabetic
rat eyes were enucleated at 1, 3, and 6 months, and the retinae
were quickly collected and transferred into lysis buffer. Total
RNA  was  isolated  using  a  Triozol  kit  (Invitrogen  Life
Technologies,  Shanghai,  China),  according  to  the
manufacturer’s  instructions.  First-strand  cDNA  was
synthesized  from  0.1  μl  of  total  RNA  in  20  μl  buffer
containing 4 μl MgCl2, 1 μl oligo(dT) or random hexamer,
2 μl deoxy-ribonucleoside triphosphate (dNTP), 1 μl AMV
reverse transcriptase, and 0.5 μl RNase inhibitor. Based on the
manufacturer’s  instructions,  the  reaction  mixture  was
incubated at 30 °C for 10 min, 42 °C for 1 h, heat inactivated
at 99 °C for 5 min, 5 °C for 5 min, and then the cDNAs pooled
from  two  reactions  with  different  primers.  PCR  was
performed  with  4  μl  of  pooled  cDNA  in  20  μl  buffer
containing 0.5 μl DNA polymerase, and 4 μl of the primers.
The primer sequences for VEGF, hPEDF, and glyceraldehyde
phosphate dehydrogenase (GAPDH; synthesis by TAKARA
Biotechnology  CO,  LTD,  Dalian,  China)  are  as  follows;
VEGF: forward primer 5′-GCA CCC ACG ACA GAA GG-3′,
reverse  primer  5′-TGA  ACG  CTC  CAG  GAT  TTA-3′,
fragment length 416 bp; PEDF: forward primer 5′-CAG AAG
AAC CTC AAG AGT GCC-3′, reverse primer 5′-CTT CAT
CCA  AGT  AGA  AAT  CC-3′,  fragment  length  310  bp;
GAPDH: forward primer 5′-ACC ACA GTC CAT GCC ATC
AC-3′, reverse primer 5′-TCC ACC ACC CTG TTG CTG
TA-3′, fragment length 452 bp. The reaction was cycled as
follows: 2 min at 94 °C; 30 cycles of 30 s at 94 °C, 30 s at
57 °C and 1 min at 72 °C, and a final extension of 10 min at
72 °C. PCR products were run on a 1.5% agarose gel.
Western blot analysis: Normal and diabetic rat eyes were
enucleated at 1, 3, and 6 months and the retinae dissected free
from surrounding tissue and then homogenized by sonication.
The  insoluble  pellet  was  removed  by  centrifugation  at
10,000× g for 15 min, and the protein concentration of the
supernatant measured using a Coomassie brilliant blue protein
assay (Jiancheng Bioengineering Institute, Nanjing, China).
The soluble proteins (100 µg) were then resolved by sodium
dodecyl sulfate PAGE (SDS–PAGE; 12% polyacrylamide gel
for hPEDF, intercellular adhesion molecule-1 (ICAM-1) and
occludin,  15%  polyacrylamide  gel  for  VEGF)  and
electrotransferred to a Hybond ECL nitrocellulose membrane
(Amersham International, Piscataway, NJ). The membrane
was  blotted  with  polyclonal  anti-hPEDF  antibody  (Boster
Biotechnology LTD, Wuhan, China), polyclonal anti-VEGF
antibody  (Boster  Biotechnology),  anti-ICAM-1  antibody
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(1:1,000;  Zymed  Laboratory,  San  Francisco,  CA).  The
concentrations  of  primary  antibodies  were  1:100.  The
membranes  were  stripped  and  re-immunostained  with  an
antibody specific to β-actin (1:5,000 dilution; Sigma) as a
normalization  procedure.  The  densities  of  bands  were
measured with FluorChem version 2.0 imaging system (Alpha
Innotech Corporation, San Leandro, CA) and normalized by
β-actin as semiquantitation of protein.
Measurement  of  blood–retinal  barrier  breakdown:  BRB
breakdown  was  quantified  by  measuring  albumin  leakage
from  retinal  blood  vessels  using  the  Evans  blue  albumin
method,  as  described  previously  [14]  with  minor
modifications. Briefly, Evans blue dye (Sigma) was dissolved
in normal saline (30 mg ml−1). The rats were anesthetized with
ketamine (80 mg kg−1) by intraperitoneal injection and the dye
(45 mg kg−1) injected over 10 s through the caudal vein. The
rats were kept on a warm pad for 2 h to ensure complete dye
circulation. Two minutes after the injection of Evans blue,
0.2 ml blood was drawn from tail vein to obtain the initial
Evans blue plasma concentration. Subsequently, at 15-min
intervals, 0.1 ml blood was drawn up to 2 h after injection to
obtain the time-averaged Evans blue plasma concentration. At
exactly 2 h after infusion, 0.2 ml blood was drawn to obtain
the final Evans blue plasma concentration, after which the
chest cavity was opened and the rats transcardially perfused
via the left ventricle for 2 min (120 mmHg) with 37 °C 1%
paraformaldehyde in citrate buffer (pH 4.2) to fix the retinae
and clear excess dye from the blood vessels. Immediately after
perfusion, the eyes were enucleated and the retinae dissected
free from surrounding tissue. After thoroughly drying the
retinae,  they  were  weighed,  and  the  Evans  blue  dye  was
extracted  from  the  tissue  by  incubating  each  sample  in
120 μl formamide (Sigma, ShangHai, China) for 18 h at 70 °C.
The extract was centrifuged at 81,500× g for 45 min at 4 °C,
and  then  the  absorbance  in  50  μl  of  the  supernatant  was
measured at 620 nm and 740 nm. The concentration of Evans
blue was calculated from a standard curve and normalized
according  to  the  retinal  dry  weight  and  expressed  in  ml
plasma×g retinal dry wt−1 h−1.
Statistical  analysis:  All  values  were  given  as  the  mean
±standard  deviation.  One-way  ANOVA  and  Pearson
correlation analysis were used for statistical analyses. A p
value of ≤0.05 was considered statistically significant. All
data were analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL).
RESULTS
Expression of GFP in retina mediated by rAAV2 vector: GFP
has the property of autoradiation of green fluorescence. Using
a fluorescence microscope, GFP expression was evaluated
after 1, 3 and 6 months of rAAV2-CMV-GFP injection. As
shown in Figure 1, no hyperfluorescence signal was observed
in normal retinae. After 1 month, hyperfluorescence signals
were  detected  in  the  ganglion  cell  layer  of  retinae  with
rAAV2-CMV-GFP  injection.  Gradually,  the  area  of
fluorescence extended to most retinae after 3 months. Finally,
Figure 1. Expression of green fluorescent protein in retinae mediated by recombinant adeno-associated virus vector. A: No fluorescence signals
were found in normal retinae. B: One month later, fluorescence signals were detected in the ganglion cell layer of retinae injected with
recombinant adeno-associated virus vector-cytomegalovirus-green fluorescent protein. C, D: The area of fluorescence extended to most of
the retinae after 3 months (C) and after 6 months (D), fluorescence signals had been detected in all retinae. The orientation of the sections
was from superior to inferior. The bar is 200 μm, and magnification is 200×.
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months.
PEDF expression in the retina of diabetic rats after vector
injection: Expression of hPEDF mRNA of diabetic rats and
normal control rats was determined by RT–PCR at 1, 3, and
Figure  2.  Expression  of  pigment
epithelium-derived  factor  in  retinae
after  intravitreal  injection.  A:  The
expression  of  human  pigment
epithelium-derived  factor  (hPEDF)
mRNA in injected retinae was enhanced
and increased over time. No expression
were detected in the uninjected control
rats. B: The protein expression of PEDF
decreased in the paired control retinae
but  significantly  increased  in  treated
eyes  (p<0.01)  compared  to  paired
controls  or  normal  control  eyes
(p<0.01).  Values  of  treatment  were
compared to that of normal control *p
value <0.05, ** p value<0.01. Values of
treatment  were  compared  to  that  of
paired  control,  #  p  value  <0.01.
Abbreviations:  DM1  represents
diabetes  1  month,  DM3  represents
diabetes  3  months,  DM6  represents
diabetes  6  months,  CON  represents
normal control group, CONf represents
sham-injected normal control group, t
represents treatment.
TABLE 1. EXPRESSION OF HPEDF MRNA
Groups Paired control Treatment
CON 0 0
DM1 0 0.34±0.03
DM3 0 0.47±0.04*
DM6 0 0.62±0.05*
        The asterisk indicated compared to 1 month p value<0.05. Abbreviations: CON represents normal control group, DM1 represents
        diabetes 1 month, DM3 represents diabetes 3 months, DM6 represents diabetes 6 months.
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2387Figure  3.  Expression  of  vascular
endothelial growth factor in retinae after
intravitreous  injection.  A:  Vascular
endothelial  growth  factor  (VEGF)
mRNA  in  paired  control  retinae
increased with time to almost twice that
in  the  normal  control  eyes  after  6
months.  Similarly,  the  amount  of
VEGF  mRNA  in  the  retinae  of  all
treatment groups was statistically higher
than the amount in normal retinae but
was significantly lower than the amount
in  the  respective  paired  control  eyes
(p<0.01). B: The expression of VEGF
protein in treated retinae paralleled the
expression of VEGF mRNA. Values of
treatment  were  compared  to  that  of
normal control * p value <0.05, ** p
value<0.01. Values of treatment were
compared to that of paired control # p
value  <0.01.  Abbreviations:  DM1
represents  diabetes  1  month,  DM3
represents  diabetes  3  months,  DM6
represents  diabetes  6  months,  CON
represents normal control group, CONf
represents sham-injected normal control
group, t represents treatment.
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23886 months after the injection of rAAV2-CMV-hPEDF. Bands
about 310 bp corresponding to the hPEDF mRNA primer
were not detected in normal eyes and paired control eyes,
while hPEDF mRNA primer expression was identified in the
retinae  of  rAAV2-CMV-hPEDF  injected  eyes  and
significantly  increased  over  time  (p<0.05  n=13,  13,  12,
respectively;  Figure  2A),  reaching  a  maximum  at  the  6
months.
Western blot analysis also showed that the expression of
PEDF  increased  significantly  in  vector-injected  eyes
compared to the paired control eyes (p<0.01), which showed
a decreased PEDF, and normal control eyes (p<0.01). These
results were consistent with findings on the expression of
PEDF at the mRNA level (Figure 2B, Table 1).
rAAV2-CMV-hPEDF injections downregulated expression of
VEGF:  To  assess  the  relationship  between  VEGF  and
PEDF, we analyzed the expression of VEGF in retinae, at both
mRNA and protein levels, at 1, 3, and 6 months after vector
injection, by using RT–PCR and western blots. VEGF mRNA
in paired control retinae increased with time to almost twice
that in the normal control eyes after 6 months. Similarly, the
amount of VEGF mRNA in the retinae of all treatment groups
was statistically higher than that in the normal retinae (p<0.05,
Figure  3A)  but  was  significantly  lower  than  that  in  the
respective  paired  control  eyes  (p<0.01).  Furthermore,  a
significant negative correlation between the expression of
VEGF  mRNA  and  PEDF  mRNA  (r=-0.732,  p<0.01)  was
observed.
The  expression  of  VEGF  protein  in  rAAV2-CMV-
hPEDF-injected  retinae  showed  similar  trends  to  that  of
VEGF  mRNA  (Figure  3B),  which  indicated  that
overexpression of hPEDF in the retina downregulated the
expression of VEGF at both mRNA and protein levels. In the
treated retinae, the value of VEGF against PEDF was nearly
equal to that in the normal control and was lower relative to
the paired control retinae. However, the ratio of VEGF:PEDF
in paired control retinae increased with time to almost eight
times that of the normal control’s value after 6 months (Table
2).
hPEDF  upregulated  retinal  occludin  but  downregulated
retinal ICAM-1: Western blot was used to assess the effect of
hPEDF on occludin and ICAM-1 protein levels after retinal
hPEDF gene transfection. Although retinal occludin in treated
eyes did not differ significantly from the levels of paired
control eyes after 1 month, at 3 and 6 months its level in
rAAV2-CMV-hPEDF-injected  eyes  increased  significantly
compared with paired control eyes (Figure 4) and reached
levels similar to that seen in the normal eyes at 6 months. In
TABLE 2. EXPRESSION OF VEGF IN THE RETINAE
Groups
VEGF protein VEGFmRNA VEGFp/PEDFp
Paired control Treatment Paired control Treatment Paired control Treatment
CON 0.25±0.04 0.28±0.04 0.40±0.02 0.50±0.02 0.53 0.58
DM1 0.52±0.04** 0.37±0.03#* 0.69±0.03** 0.60±0.02# 1.3 0.76
DM3 0.63±0.08** 0.38±0.02#* 0.83±0.04** 0.66±0.03# 1.85 0.64
DM6 0.86±0.08** 0.41±0.09#** 0.87±0.04** 0.63±0.03## 4.42 0.61
         Values of treatment were compared to that of normal control * p value <0.05, ** p value<0.01. Values of treatment were
         compared to that of paired control # p value <0.05, ## p value<0.01. PC=paired control. Abbreviations: T represents treatment,
         CON represents normal control group, DM1 represents diabetes 1 month, DM3 represents diabetes 3 months, DM6 represents
         diabetes  6 months, VEGF represents vascular endothelial growth factor, PEDF represents pigment epithelium-derived factor,
         VEGFp represents VEGFprotein, PEDFp represents PEDF protein 1.
TABLE 3. EXPRESSION OF ICAM-1 AND OCCLUDIN IN THE RETINAE
Groups
ICAM-1 Occludin
Paired control Treatment Paired control Treatment
CON 0.14±0.01 0.15±0.01 0.52±0.03 0.52±0.04
DM1 0.40±0.02* 0.31±0.01#* 0.35±0.02* 0.35±0.01*
DM3 0.65±0.02* 0.36±0.01#* 0.26±0.02* 0.45±0.03*#
DM6 0.70±0.02* 0.44±0.03#* 0.21±0.02* 0.55±0.02#
         *Values of treatment were compared to that of normal control, p value <0.05. #Values of treatment were compared to that of
         paired control, p value <0.01. Abbreviations: PC represents paired control, T represents treatment, CON represents normal
         control group, DM1 represents diabetes 1 month, DM3 represents diabetes 3 months, DM6 represents diabetes 6 months,
         ICAM-1 represents intercellular adhesion molecule-1.
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2389contrast, the retinal occludin level in paired control eyes was
significantly lower than that in the treatment and normal eyes.
On the other hand, the expression of ICAM-1 increased in
paired  controls  and  treated  retinae  compared  with  its
expression  in  normal  eyes  (p<0.05).  Its  level  remained
significantly lower in the injected retinae (p<0.01) compared
with  paired  controls  (Table  3)  .There  was  a  significant
negative  correlation  between  ICAM-1  and  occludin
(r=-0.754, p<0.01).
rAAV2-CMV-hPEDF  injections  suppressed  blood–retinal
barrier  breakdown:  To  determine  the  permeability  of  the
retinal vasculature in diabetic rats and the effect of PEDF on
the  BRB,  we  intravenously  injected  rats  with  Evans  blue
albumin on the last day of months 1, 3, and 6. Our standard
curves  shown  in  Figure  5A  confirm  the  reliable  linear
relationship  between  background-subtracted  absorbance
(620–740 nm) and Evans blue concentration in formamide
from  1  to  80  μg  ml−1  (r=0.999,  regression  equation
y=0.0038×–0.003).
Figure 4. The protein levels of occludin
and intercellular adhesion molecule-1 in
paired  control  retinae  significantly
decreased and increased, respectively,
over time. A: Western blots had been
used to assess occludin and intercellular
adhesion molecule-1 (ICAM-1) protein
levels in retinae. B: The expression of
occludin  in  treated  eyes  increased
significantly  at  months  3  and  6
compared with paired control eyes. C:
The expression of ICAM-1 in treated
eyes was obviously lower than that in
the paired control eyes (p<0.01) but still
higher than that in normal control eyes
(p<0.01).  *Values  of  treatment  were
compared to that of normal control, p
value <0.05. #Values of treatment were
compared to that of paired control, p
value  <0.01.  Abbreviations:  DM1
represents  diabetes  1  month,  DM3
represents  diabetes  3  months,  DM6
represents  diabetes  6  months,  CON
represents normal control group, CONf
represents sham-injected normal control
group, t represents treatment.
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2390Leakage from the retinal vasculature became more and
more severe with the progression of diabetes in the paired
control eyes (Figure 5B) and it reached a maximum by the
month 6 (50.48±13.79) with a fourfold increase compared
with that in normal control eyes (14.04±4.54, p<0.01). The
damage to the BRB was less severe in the treatment group
compared with the paired control group, especially at the 3
and 6 months (p<0.05). Nevertheless, Evans blue levels in the
treatment group were all significantly higher than levels seen
in normal control retinae (p<0.05).
DISCUSSION
Our study demonstrated that single intravitreal injection of
rAAV-PEDF  relieved  BRB  breakdown  in  STZ-induced
diabetic rats for 6 months. The effect was associated with the
downregulation  of  retinal  VEGF  mRNA  and  ICAM-1
expression  and  concomitant  upregulation  of  occludin
Figure 5. Measurement of blood–retinal
barrier  breakdown  by  Evans  blue.  A:
Bar  graph  show  standard  curve  for
Evans blue concentration in formamide
(background-subtracted  absorbance  at
620–740 nm; concentration from 1 to 80
μg/ml).  B:  Histogram  shows  retinal
Evans blue leakage in diabetic rats at
different  times.  *Values  of  treatment
were compared to that of normal control
* p value <0.05, ** p value<0.01. Values
of treatment were compared to that of
paired  control  #  p  value  <0.05,  ##  p
value<0.01
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2391expression.  rAAV2-CMV-hPEDF  partly  ameliorated  the
retinal VEGF/PEDF imbalance and thus reduced the vascular
permeability and subsequently restored BRB.
Diabetic  macular  edema  is  a  common  pathological
feature  in  DR  and  responsible  for  vision  loss.  BRB
breakdown,  a  characteristic  sign  of  early  DR,  and  the
subsequent increase in vascular permeability are believed to
play major roles in the development of DME and progression
of  DR.  To  date,  the  exact  mechanisms  underlying  the
pathogenesis of the changes of BRB in DR are unclear.
Accumulating clinical evidence has suggested that VEGF
plays an important role in DME in early diabetes [10,15,16].
VEGF is a potent vascular permeability factor [17], which
significantly  increased  endothelial  permeability
(approximately twofold) after 24 h co-incubation with retinal
capillary endothelial cells [18], and caused BRB breakdown
after sustained intravitreal release in rabbits [19,20]. Previous
studies  have  shown  that  the  levels  of  VEGF  and  VEGF
receptor were higher in DR [21,22]. In the early stages of STZ-
induced  diabetes  in  rats,  retinal  VEGF  mRNA  levels
dramatically  increased  and  were  correlated  with  retinal
vascular permeability. However, this early BRB breakdown
was successfully prevented by VEGF TrapA40, a soluble
VEGF receptor Flt/Fc [23]. In this study, we have confirmed
the association between the increases in retinal VEGF levels
and  BRB  breakdown  in  animals  with  induced  diabetes,
suggesting that the overexpression of retinal VEGF induces
BRB breakdown.
PEDF is an endogenous angiogenic inhibitor in the eye
and can counterbalance the angiogenic effect of VEGF and
suppress neovascularization in PDR and age-related macular
degeneration (AMD) [24–27]. Clinical studies have shown
that decreased expression of PEDF in the retina and vitreous
was associated with DME [10]. High levels of PEDF might
reduce vascular leakage induced by VEGF [11] or diabetes
[18], suggesting that PEDF is involved in the regulation of
vascular  permeability.  Therefore  PEDF  therapy  may  be
effective not only for PDR but also for DME.
We  consider  an  ideal  theraputic  strategy  for  DME
treatment would be to develop an approach involving single
administration of vectors to sustain the long-term expression
of  a  suitable  therapeutic  gene.  rAAV  vectors  are  highly
efficient gene delivery systems that can facilitate long-term
transduction [13,24]. Although AAV-PEDF has been used to
inhibit retinal and choroidal neovascularization induced by
laser or hypoxia [13,27], to our knowledge, this is the first
time  for  the  application  of  AAV-PEDF  in  eyes  of  STZ-
induced diabetic animals. Indeed, our study has shown that
PEDF  expression  in  the  retina  lasted  for  6  months  after
rAAV2-CMV-hPEDF  injection,  which  potentially  enables
clinicians to avoid repeated intravitreal injections. In addition,
we demonstrated that intravitreal injections of rAAV2-CMV-
hPEDF suppressed BRB breakdown by downregulating the
expression of VEGF in diabetic rats. In our study, retinal
VEGF  mRNA/protein  expression  and  BRB  breakdown
decreased  in  rAAV2-CMV-hPEDF-transfected  eyes
compared with the contralateral control eyes injected with
rAAV2-CMV-GFP. The retinal balance of VEGF/PEDF was
partially corrected in these diabetic rats by downregulation of
VEGF mRNA expression in the retina, which is consistent
with previous reports on the reduction of vascular leakage via
the  blockade  of  VEGF  with  PEDF  [11,18].  The  exact
mechanism(s)  by  which  PEDF  reduces  vascular  leakage
through  inhibition  of  VEGF  production  is  still  under
investigation.
VEGF-mediated upregulation of ICAM-1, an adhesion
receptor for leukocytes, may contribute to the observed retinal
vascular  changes,  such  as  vascular  leakage  and  local
nonperfusion  in  early  diabetic  retinopathy  [28,29].  This
conclusion is based on two lines of evidence. First, previous
studies have demonstrated that the expression of both retinal
VEGF mRNA [23] and ICAM-1 [30] were upregulated in
rodent models of diabetic retinopathy and ICAM-1 levels
were decreased by suppressing VEGF activity associated with
a decrease in BRB breakdown and leukostasis [31]. Second,
studies in nondiabetic rats found that retinal ICAM-1 was
upregulated in response to VEGF [32] and the overexpression
of ICAM-1 mRNA induced by VEGF via the phospholipase
c/nuclear factor-kB (PLC/ NF-kB) pathway in endothelial
cells  [33].  Inhibition  of  ICAM-1  activity  significantly
suppressed  VEGF-induced  hyperpermeability  and
leukostasis.  These  data  suggest  that  ICAM-1  is  a  crucial
mediator of the VEGF effect on vascular permeability [34].
In our study, retinal ICAM-1 decreased in the eyes receiving
rAAV2-CMV-hPEDF  injection,  suggesting  that  PEDF
decreased ICAM-1 expression in the diabetic retina.
The tight junctions between retinal vascular endothelial
cells constitute an essential structural component of the BRB.
We observed that the levels of occludin, a barrier protein,
decreased by around 50% to 60% between 3 and 6 months
after induction of diabetes, which is consistent with the results
of Antonetti and colleagues [35]. VEGF not only decreases
occludin  expression  [18]  but  also  stimulates  its
phosphorylation and redistribution [36,37] by activating the
phosphatidylinositol  3-kinase/protein  kinase  C  (PKC)
isoform pathway [38], which subsequently induces elevated
vascular  permeability.  This  implies  that  a  lowering  and
redistribution of retinal occludin induced by overexpression
of VEGF may be responsible for BRB breakdown in early DR
[35]. Ho and coworkers [39] reported that PEDF prevented
the redistribution of occludin in retinal pigment epithelium
(RPE)  cells  from  being  damaged  by  oxidants.  Our  study
showed a significant negative relationship between retinal
VEGF and occludin. Intravitreal injection of rAAV2-CMV-
hPEDF significantly increased retinal occludin expression in
STZ-induced diabetic rats, with a concomitant reduction in
retinal  vascular  permeability.  We  suggest,  therefore,  that
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retinal occludin content in these rats through inhibition of
VEGF. These results suggest that transgenic expression of
rAAV2-CMV-hPEDF may be a useful strategy for long-term
preventive or adjunctive therapy for DME.
Although  the  findings  reported  here  have  important
clinical implications for DR therapy, the safety issues and
immune  response  induced  by  vectors  should  be  studied
further. Recently, Li and colleagues found that intravitreal
injection  of  AAV  vectors  in  mice  generated  a  humoral
immune  response  against  AAV  capsid,  which  suppressed
vector expression upon re-administration via the same route
into the partner eye [40]. Application of an AAV vector with
intravitreal injection would be limited if a similar immune
response is found in humans. However, this conclusion is
worthy of further investigation because the vitreous cavity and
subretinal  space  are  immune-privileged  sites  [41],  BRB
isolates  them  from  the  main  circulation,  and  findings  in
animals  cannot  be  simply  extrapolated  because  humans
possess a more complicated immune system. Many factors
could  affect  the  immune  response  against  AAV-mediated
ocular  gene  transfer  in  diabetic  eyes,  such  as  vitreous
hemorrhages and neovascularization, which compromise the
immune  privilege  of  the  eye.  Further  studies  need  to  be
performed to address these issues.
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